FDA Guidance For Diversity In Clinical Trials: What You Need To Know
Source: Florence Healthcare
By Taylor Davidson, Florence Healthcare

The FDA’s newest guidance, “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials,” took the clinical research world by storm.
While diversity, equity, and inclusion have been major focuses for clinical research teams for a long time, sponsors and sites were excited and surprised to receive explicit FDA guidance in April 2022.
But what do clinical research teams need to know from the guidance, and how can we prepare to incorporate it?
access the Article!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
Florence Healthcare
This website uses cookies to ensure you get the best experience on our website. Learn more